Osteoporosis Drugs Global Market Report 2024

Description

Osteoporosis drugs are medications designed to increase bone mineral density, reducing the risk of fractures. They are used both in the treatment and prevention of fractures, aiming to strengthen bones and prevent bone loss associated with osteoporosis.

The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.

The osteoporosis drugs market research report is one of a series of new reports from The Business Research Company that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12 billion in 2023 to $12.48 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The growth observed in the historical period can be attributed to an aging population, heightened awareness and diagnosis, lifestyle factors, and government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The forecasted growth is driven by continuing trends of an aging population, advancements in treatment options, increased focus on men's bone health, patient education, and global health policies. Key trends include personalized medicine, exploration of combination therapies, emphasis on fracture prevention, research and development in novel drug targets, and collaborative efforts for drug development.

The increasing prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis, a bone disease characterized by a decline in bone mineral density and mass or changes in bone quality and structure, is often associated with low calcium intake. Osteoporosis drugs play a crucial role in increasing bone mineral density and preventing fractures in individuals affected by the condition. For example, as of May 2022, statistics from Amgen, a US-based biotechnology company, revealed that osteoporosis causes approximately 1.5 million fractures in the United States annually, resulting in associated costs amounting to $19 billion. Furthermore, the annual number of fractures caused by osteoporosis is projected to increase by 68% from 2018 to 2040, rising from 1.9 million to 3.2 million. Consequently, the surging prevalence of osteoporosis stands as a key factor driving the growth of the osteoporosis drug market.

The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.

Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.

Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.

In August 2021, Nestle Health Science, a Switzerland-based provider of nutrition solutions, diagnostics, devices, and drugs, successfully acquired the core brands of Bountiful Company for an undisclosed amount. This strategic acquisition is aimed at enhancing Nestle Health Science's portfolio with trusted products and methodologies, further advancing its mission to improve the health of clients globally. Bountiful Company, based in the United States, is recognized for its joint care supplement brand.

Major companies operating in the osteoporosis drugs market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Union Chimique Belge, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Enzene Biosciences Ltd., Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Ligand Pharmaceuticals Incorporated, Theramex, Radius Health Inc., Actavis PLC, Strides Pharma Science Limited, Apotex Inc.

North America was the largest region in the osteoporosis market in 2023. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors
2) By Administration: Oral; Injectable
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
4) By Application: Primary Osteoporosis; Secondary Osteoporosis
Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r15889

1. Executive Summary

2. Osteoporosis Drugs Market Characteristics

3. Osteoporosis Drugs Market Trends And Strategies

4. Osteoporosis Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Osteoporosis Drugs Market Size and Growth

5.1. Global Osteoporosis Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Osteoporosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Osteoporosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Osteoporosis Drugs Market Segmentation

6.1. Global Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Bisphosphonates
Selective Estrogen Receptor Modulators (SERMs)
RANK Ligand Inhibitors
6.2. Global Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Injectable
6.3. Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Retail Pharmacies
Hospital Pharmacies
Online Sales
6.4. Global Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Primary Osteoporosis
Secondary Osteoporosis

7. Osteoporosis Drugs Market Regional And Country Analysis

7.1. Global Osteoporosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Osteoporosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Osteoporosis Drugs Market

8.1. Asia-Pacific Osteoporosis Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Osteoporosis Drugs Market

9.1. China Osteoporosis Drugs Market Overview
9.2. China Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Osteoporosis Drugs Market

10.1. India Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Osteoporosis Drugs Market

11.1. Japan Osteoporosis Drugs Market Overview
11.2. Japan Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Osteoporosis Drugs Market

12.1. Australia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Osteoporosis Drugs Market

13.1. Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Osteoporosis Drugs Market

14.1. South Korea Osteoporosis Drugs Market Overview
14.2. South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Osteoporosis Drugs Market

15.1. Western Europe Osteoporosis Drugs Market Overview
15.2. Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Osteoporosis Drugs Market

16.1. UK Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Osteoporosis Drugs Market

17.1. Germany Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Osteoporosis Drugs Market

18.1. France Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Osteoporosis Drugs Market

19.1. Italy Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Osteoporosis Drugs Market

20.1. Spain Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Osteoporosis Drugs Market

21.1. Eastern Europe Osteoporosis Drugs Market Overview
21.2. Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Osteoporosis Drugs Market

22.1. Russia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Osteoporosis Drugs Market

23.1. North America Osteoporosis Drugs Market Overview
23.2. North America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Osteoporosis Drugs Market

24.1. USA Osteoporosis Drugs Market Overview
24.2. USA Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Osteoporosis Drugs Market

25.1. Canada Osteoporosis Drugs Market Overview
25.2. Canada Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Osteoporosis Drugs Market

26.1. South America Osteoporosis Drugs Market Overview
26.2. South America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Osteoporosis Drugs Market

27.1. Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Osteoporosis Drugs Market

28.1. Middle East Osteoporosis Drugs Market Overview
28.2. Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Osteoporosis Drugs Market

29.1. Africa Osteoporosis Drugs Market Overview
29.2. Africa Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Osteoporosis Drugs Market Competitive Landscape And Company Profiles

30.1. Osteoporosis Drugs Market Competitive Landscape
30.2. Osteoporosis Drugs Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bristol Myers Squibb Company
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Osteoporosis Drugs Market Other Major And Innovative Companies

31.1. GlaxoSmithKline PLC
31.2. Eli Lilly and Company
31.3. Amgen Inc.
31.4. Novo Nordisk A/S
31.5. Asahi Kasei Pharma Corporation
31.6. Viatris Inc.
31.7. Teva Pharmaceutical Industries Ltd
31.8. Mylan N.V.
31.9. Daiichi Sankyo Company Limited
31.10. Union Chimique Belge
31.11. Sun Pharmaceutical Industries Ltd.
31.12. Ipsen
31.13. Kyowa Kirin Co. Ltd.
31.14. Dr. Reddy's Laboratories Ltd.
31.15. Cipla Limited

32. Global Osteoporosis Drugs Market Competitive Benchmarking

33. Global Osteoporosis Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Osteoporosis Drugs Market

35. Osteoporosis Drugs Market Future Outlook and Potential Analysis

35.1 Osteoporosis Drugs Market In 2028 - Countries Offering Most New Opportunities
35.2 Osteoporosis Drugs Market In 2028 - Segments Offering Most New Opportunities
35.3 Osteoporosis Drugs Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer